Recruiting
Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants - IM101-675
Actualizada: 13 agosto, 2019 | ClinicalTrials.gov
Imprimir Resumen
Detalles del ensayo
Género(s)
Rango de edad
Ubicación(es)
Recruiting
Opciones de tratamiento
Inclusion Criteria: - Patients 18 years of age at enrollment - Patients who signed an informed consent - Patients diagnosed with PsA as per the criteria of the Classification of Psoriatic Arthritis (CASPAR) Study Group17 - Patients naïve of abatacept and who at their physician's discretion initiate abatacept - Patients meeting criteria for abatacept treatment for PsA as specified in the German label Exclusion Criteria: - Patients who are currently included in any interventional clinical trial in PsA/RA Other protocol defined criteria inclusion/exclusion criteria could apply
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
